Compare NKSH & STXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NKSH | STXS |
|---|---|---|
| Founded | 1891 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.2M | 210.0M |
| IPO Year | N/A | 2004 |
| Metric | NKSH | STXS |
|---|---|---|
| Price | $33.60 | $2.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 13.0K | ★ 471.8K |
| Earning Date | 01-22-2026 | 11-11-2025 |
| Dividend Yield | ★ 4.50% | N/A |
| EPS Growth | ★ 41.35 | N/A |
| EPS | ★ 2.04 | N/A |
| Revenue | ★ $51,980,000.00 | $30,075,000.00 |
| Revenue This Year | $2.95 | $24.48 |
| Revenue Next Year | $9.97 | $29.98 |
| P/E Ratio | $16.43 | ★ N/A |
| Revenue Growth | ★ 19.63 | 19.62 |
| 52 Week Low | $23.75 | $1.54 |
| 52 Week High | $33.92 | $3.59 |
| Indicator | NKSH | STXS |
|---|---|---|
| Relative Strength Index (RSI) | 73.37 | 44.44 |
| Support Level | $29.79 | $2.34 |
| Resistance Level | $30.72 | $2.44 |
| Average True Range (ATR) | 0.92 | 0.10 |
| MACD | 0.40 | 0.03 |
| Stochastic Oscillator | 96.46 | 55.17 |
National Bankshares Inc is a bank holding company. It focuses on lending to small and mid-sized businesses and individuals. The types of loans it offers include commercial and agricultural, commercial real estate, construction for commercial and residential properties, residential real estate, home equity, and various consumer loan products. It also operates an insurance and brokerage subsidiary, National Bankshares Financial Services, Inc. The company earns its revenues from interest and fees on loans, non-interest income, and investments.
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.